title: Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
abstract: Vascular endothelial growth factor (VEGF) targeted therapy, either alone or in combination with chemotherapy, has become the standard of care in several solid tumours, including colorectal cancer, renal-cell carcinoma, breast cancer, non-small-cell lung cancer, and glioblastoma. VEGF is crucial in the process of angiogenesis and wound healing and, thus, its inhibition has the potential to affect wound healing in patients undergoing surgery. In this review, we summarise the data available on the use of VEGF-targeted therapies, and their effect on perioperative wound complications. Surgery in patients receiving VEGF-targeted therapies seems to be safe when an appropriate interval of time is allowed between surgical procedures and treatment. Recommendations regarding this interval are provided in a disease and agent site-specific manner. We also discuss complications arising from the use of VEGF-directed therapies that might require surgical intervention and the considerations important in their management. At this juncture, safety data on the use of VEGF-targeted therapies in the perioperative period are sparse, and investigators are urged to continue to study this issue prospectively in current and future clinical trials to establish firm guidelines.
authors.affiliation: Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA.
authors.forename: Debashish
authors.initials: D
authors.lastname: Bose
authors.forename: Funda
authors.initials: F
authors.lastname: Meric-Bernstam
authors.forename: Wayne
authors.initials: W
authors.lastname: Hofstetter
authors.forename: David A
authors.initials: DA
authors.lastname: Reardon
authors.forename: Keith T
authors.initials: KT
authors.lastname: Flaherty
authors.forename: Lee M
authors.initials: LM
authors.lastname: Ellis
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects; D000068258:Bevacizumab; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects; D020360:Neoadjuvant Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011183:Postoperative Complications / Q000139:chemically induced* / Q000517:prevention & control; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects; D000077157:Sorafenib; D000077210:Sunitinib; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D000077210:Sunitinib